STTK — Shattuck Labs, Inc.

Is STTK overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Strong Oversold As of November 17, 2026

Shattuck Labs, Inc. (STTK) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $4.66. The rating moved from Oversold to Strong Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Shattuck Labs, Inc. (STTK) presents a mixed profile: potential upside if the company can demonstrate clinical progress, secure partnerships or access non-dilutive capital, and capture readthroughs from the broader shift to at‑home specialty care. However, visibility is limited by the absence of recent filings and social/research coverage, leaving liquidity, cash runway and near‑term milestones unclear. Given the high binary nature of biotech/device outcomes, short-term performance will likely be driven by newsflow and financing dynamics rather than steady revenue growth. Monitor upcoming disclosures, any clinical/regulatory timelines, and financing activity closely for changes to the outlook.

Key factors

  • Shattuck Labs, Inc. (STTK) is a small-cap healthcare/device/biotech issuer with limited public disclosure and low liquidity, which increases volatility and uncertainty.
  • Sector thematic tailwinds for at‑home and specialty care delivery could be a structural positive if Shattuck's pipeline or technologies address outpatient/home administration.
  • Lack of recent EDGAR/filing analysis and no available social sentiment data constrain visibility into cash runway, revenue trends, and near-term milestones.
  • Convertible-debt / financing environment in mid-cap biotech creates potential dilution pressure across the sector; access to non-dilutive financing varies by issuer size.
  • Market risk-on bias toward growth names could help sentiment-sensitive small-caps if Shattuck reports positive clinical/commercial updates.
  • Key near-term catalysts would be clinical readouts, regulatory decisions, partner/licensing announcements or material financing; absent those, price action likely driven by newsflow and liquidity.

Risks

  • Insufficient public financial disclosure; unclear cash runway and potential need for dilutive financing.
  • Clinical or regulatory setbacks for product candidates would materially reduce valuation.
  • Reimbursement and commercial adoption risk if product requires payer coverage or healthcare-provider acceptance.
  • High market volatility and low trading liquidity can lead to abrupt price swings unrelated to fundamentals.
  • Competition from larger device and biopharma companies with greater commercialization and distribution resources.
  • Sector-wide pressures (e.g., convertible issuance, macro risk-off) that can depress small-cap biotech valuations even with positive fundamentals.

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for STTK — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.